On the heels of the premiere of its first-ever Spanish-language Cologuard campaign, Exact Sciences is doubling down on its ...

Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year ...

Cologuard is an at-home colon cancer screening kit that detects changes in genetic material indicating potential cancer or polyps. Medicare covers one kit per year under Original Medicare (Parts A and ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

At the beginning of October, the FDA approved the Cologuard Plus test, a next-generation, multitarget stool DNA test. While fecal testing is a good option for some patients, colonoscopy remains the ...

Exact Sciences stock tumbled late Tuesday after the company cut its outlook and posted weaker-than-expected results.Shares of ...

Enter Cologuard, the at-home colon cancer screening test for people aged 45 and older. Perhaps best known by audiences for its cheeky approach to advertising, the Exact Sciences brand recently ...

The blood is tested for biomarkers and DNA mutations that are present with cancer. Another option, Cologuard, can be done at home — you collect a sample of your stool and mail it to a lab with ...

EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international ...

Exact Sciences Corp (EXAS) reports a 13% revenue increase and record free cash flow, while navigating disruptions and ...